{"doi":"10.1056/jg201205110000002","title":"Unknown","abstract":null,"journal":null,"year":null,"id":609112,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"A Review of Drug Interactions of Telaprevir and Boceprevir","abstract":"The addition of a protease inhibitor to peginterferon and ribavirin for the treatment of chronic hepatitis C virus (HCV) has significantly improved response rates compared with previous regimens. However, it has also added complexity, adverse effects, and concern about drug interactions.\n\nThe current review reports the major drug interactions of telaprevir and boceprevir and suggests approaches to managing them for special populations, including patients with …","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"23304386","pmcid":null,"openalex_id":"https://openalex.org/W2599978308","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.38461538,"influential_citations":0,"citation_trend":[],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://www.jwatch.org/jg201205110000002/2012/05/11/review-drug-interactions-telaprevir-and","host_type":"journal"}],"fields_of_study":["Hepatitis C virus research","Systemic Lupus Erythematosus Research","Heparin-Induced Thrombocytopenia and Thrombosis"],"mesh_terms":[],"keywords":["Boceprevir","Telaprevir","Medicine","Ribavirin","Virology","Drug","Hepatitis C virus","Adverse effect","Pharmacology","Protease inhibitor (pharmacology)","Internal medicine","Intensive care medicine","Virus","Viral load","Antiretroviral therapy"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-31T03:20:01.009945Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}